Coloplast reported mixed Q3 21 numbers, missing top-line estimates but beating on the bottom line. Sales were up 11% on an organic basis, driven by Urology (+82%) and ‘wound & skin care’ (+17%). Adjusted EBIT was up 16%, with the associated margin at 33%.
FY21 top-line growth is now expected to be at the lower end of 7-8%, while the adjusted EBIT margin is expected to be at the higher end of 32-33%.
We do not expect any significant changes to our estimates.
19 Aug 2021
Positive strategic update offsets soft Q3 21 showing
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive strategic update offsets soft Q3 21 showing
- Published:
19 Aug 2021 -
Author:
Virendra Chauhan -
Pages:
3
Coloplast reported mixed Q3 21 numbers, missing top-line estimates but beating on the bottom line. Sales were up 11% on an organic basis, driven by Urology (+82%) and ‘wound & skin care’ (+17%). Adjusted EBIT was up 16%, with the associated margin at 33%.
FY21 top-line growth is now expected to be at the lower end of 7-8%, while the adjusted EBIT margin is expected to be at the higher end of 32-33%.
We do not expect any significant changes to our estimates.